• High-risk (< 1:10 and/or TN>3mm); IT was offered.
• Intermediate-risk (1:10 to 1:1500); NIPT (Harmony ® Prenatal Test, Roche) was offered (if positive: IT, if negative: normal follow-up).
• Low-risk (< 1:1500); normal follow-up.
Sensitivity, specificity and false positive rate (FPR) of both screening strategies was compared. We analysed the IT and NIPT rates and the patient's opinion through an anonymous survey. Results: 2758 women were included. Sensitivity and specificity for conventional screening were 75.0% (95%CI:34.9-96.8%) and 94.7% (95%CI:94.7-96.2%) respectively, with a FPR of 4.5% (95%CI:3.8-5.3%). Sensitivity and specificity for contingent screening were 100.0% (95%CI:63. Objectives: This study aimed to assess the factors that are associated with (a) common and atypical chromosome abnormalities, and (b) the uptake of cell-free DNA (cfDNA) testing versus invasive prenatal diagnosis (IPD) alone following positive combined first trimester screening (cFTS). Methods: We reviewed a historical cohort of 1,855 Chinese women carrying singleton pregnancies with positive cFTS [at threshold 1: 250 for Trisomy (T) 21 or 1:180 for T18] in one public hospital over a five-year period. After counseling, women can choose cfDNA testing which was self-financed or IPD which was publicly funded.
All chromosome abnormalities were confirmed by invasive prenatal diagnosis (IPD) with karyotyping ± array comparative genomic hybridisation. Results: Overall, the prevalence of common and atypical abnormalities was 5.9% and 1.2% respectively. In multivariable binary logistic regression analysis, four factors (T21 risk > 1 in 100, a high risk of both T21 and T18, increased NT, or pregnancy associated plasma A (PAPP-A) <0.2 multiple of medians (MoM), and only two factors (increased NT and PAPP-A< 0.2MoM) were significant predictors of common and atypical abnormalities respectively.
The percentages of women underwent a cfDNA testing, an IPD alone, and no further testing was 37.8%, 54.9% and 7.3% respectively. Nulliparity, tertiary education or above, and working women were significant predictors of accepting cfDNA testing with adjusted Odds ratios (OR) being 1.44, 2.71, and 1.45 respectively. A high risk of Trisomy 21, and increased NT were significant predictors of accepting IPD with adjusted OR being 1.41 and 1.95 respectively while abnormal levels of serum markers were not. Conclusions: Our study has identified the factors associated with common and atypical abnormalities, and uptake of cfDNA testing versus IPD after positive cFTS. In particular, low PAPP-A was a significant predictor of atypical abnormalities, but not of accepting IPD. 
